The man who led Gilead’s autoimmune pivot heads to Boston; Novartis gets a new chief for its AI Innovation Center
The hospital’s gone now but across the street from it, there used to be a clinic, a beat-up thing with peeling paint that, in a past life, a past city, had been a bank. John Sundy was a medical student training at the hospital, in downtown Philadelphia. He walked in and saw a crowd of patients in all manner of autoimmune conditions waiting to see a tan, distinguished-looking man in a white lab coat: well-known rheumatologist Ralph DeHoratius.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 86,600+ biopharma pros reading Endpoints daily — and it's free.